Extended-release naltrexone overlooked in opioid use disorders guideline
- PMID: 30012803
- PMCID: PMC6050113
- DOI: 10.1503/cmaj.69411
Extended-release naltrexone overlooked in opioid use disorders guideline
Conflict of interest statement
Competing interests: None declared.
Comment on
-
Management of opioid use disorders: a national clinical practice guideline.CMAJ. 2018 Mar 5;190(9):E247-E257. doi: 10.1503/cmaj.170958. CMAJ. 2018. PMID: 29507156 Free PMC article. No abstract available.
References
-
- Baser O, Chalk M, Fiellin DA, et al. Cost and utilization outcomes of opioid-dependence treatments. Am J Manag Care 2011;17(Suppl 8): S235–48. - PubMed
-
- Garbutt JC, Kranzler HR, O’Malley SS, et al. Efficacy and tolerability of long-acting injectable naltrexone for alcohol dependence: a randomized controlled trial [Erratum appears in JAMA 2005; 27; 293:1978, JAMA 2005;293:2864]. JAMA 2005; 293: 1617–25. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical